Agenus Inc. — Form 10-Q Summary
Reporting period: Three and nine months ended September 30, 2020. Agenus is a clinical-stage immuno-oncology company developing antibody, vaccine and cell-therapy programs. It had no products approved for commercial sale in the U.S. and had not generated product-sales revenue.
Financial performance and position
Amounts below are in millions of U.S. dollars, except per-share amounts.
| Metric | Q3 2020 | Q3 2019 | Nine months 2020 | Nine months 2019 |
|---|---|---|---|---|
| Total revenue | $14.8 | $19.9 | $56.9 | $115.5 |
| Operating loss | $34.8 | $35.9 | $95.5 | $50.9 |
| Net loss | $51.6 | $46.3 | $145.2 | $80.7 |
| Net loss per common share, basic and diluted | $0.28 | $0.33 | $0.87 | $0.58 |
| Net cash used in operating activities | Not separately reported for the quarter | $103.5 | Cash provided: $13.1 |
- Revenue included $8.9 million of Q3 and $30.0 million of nine-month non-cash royalty revenue associated with royalties sold to Healthcare Royalty Partners (HCR). These amounts did not represent cash retained by Agenus.
- At September 30, cash and cash equivalents were $114.1 million, versus $61.8 million at December 31, 2019. Current assets were $125.5 million and current liabilities $146.9 million, a working-capital deficit of approximately $21.4 million.
- Debt principal was $20.4 million; balance-sheet debt was $20.0 million. The company also reported a $235.3 million net liability related to the sale of future royalties and milestones.
- Accumulated deficit was $1.4 billion and total stockholders’ deficit was $206.3 million. Common shares issued rose to 189.2 million from 137.8 million at year-end 2019.
Changes versus the prior comparable period
- Nine-month revenue fell by $58.6 million, primarily reflecting the absence of the $65.5 million Gilead upfront license revenue recognized in 2019. 2020 revenue included $13.9 million from the Betta license agreement.
- Nine-month operating loss increased by $44.7 million and net loss by $64.5 million. Research and development expense declined to $107.0 million from $131.5 million, while general and administrative expense rose to $39.2 million from $33.7 million.
- Nine-month net interest expense rose to $44.9 million from $29.6 million, mainly due to non-cash interest on the HCR royalty-sale liability. The company estimated the agreement’s effective annual interest rate had increased to 29.0%.
- Operating cash flow shifted from $13.1 million provided in the first nine months of 2019 to $103.5 million used in 2020. Financing cash flow was $159.2 million, including equity proceeds, which supported the increase in cash.
Outlook, developments and risks
- Management estimated September 30 cash would fund operations into the third quarter of 2021, but disclosed substantial doubt about the company’s ability to continue as a going concern for one year after filing without additional financing or other capital infusions. It said it would adjust spending as needed and was pursuing financing, partnerships and out-licensing.
- Agenus did not expect to be profitable in 2021, even if it launched its first commercial product that year. Any launch depends on regulatory approval; no commercial product revenue had yet been generated.
- The company had begun a rolling BLA submission for balstilimab monotherapy in September 2020 and expected to complete it in 2020. It expected to start a rolling submission for the balstilimab/zalifrelimab combination in Q1 2021, subject to further FDA discussion. Timelines and approval are uncertain, and a planned confirmatory trial had not yet begun.
- In November 2020, after quarter-end, Gilead notified Agenus that it would return GS-1423 and terminate the license effective February 4, 2021. The option agreements for other programs remained in force; potential future payments depend on Gilead exercising options and milestones being achieved.
- Betta paid $15.0 million upfront for Greater China rights to balstilimab and zalifrelimab; Agenus may receive up to $100.0 million in milestones plus royalties. Betta also purchased approximately $20.0 million of Agenus stock in July 2020.
- The company reported that COVID-19 had delayed approximately $45.0 million of partner milestone payments it had expected to receive in 2020. The filing also cites possible pandemic-related disruption to trials, operations and financing.
- Agenus received approximately $6.2 million under the Paycheck Protection Program and classified it as debt because forgiveness was uncertain. Its 2015 subordinated notes were amended, with $13.5 million extended to February 2023; the notes carry 8% annual interest.
- Key risks include dependence on external capital and partners, clinical and regulatory uncertainty, manufacturing and supply challenges, competition, potential dilution from further equity issuance, and possible delays to trials or commercialization. Interim clinical results may change as data mature.
Important facts for investors to verify
- Whether subsequent financings, partnerships or licensing transactions extended the cash runway beyond management’s Q3 2021 estimate, and whether the going-concern uncertainty was resolved.
- The final clinical data, FDA feedback, BLA filing and review timelines, and confirmatory-trial status for balstilimab and zalifrelimab.
- The financial and development consequences of Gilead’s return of GS-1423 and whether any option programs advance or are exercised.
- Actual cash burn, cash proceeds from equity sales, and the resulting share-count dilution; the filing reports substantial ATM issuance and additional post-quarter ATM proceeds of about $7.0 million through November 5, 2020.
- The repayment or forgiveness outcome for the PPP loan, and the cash-flow implications of the HCR royalty liability and its disclosed interest-rate estimate.